Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Losses Mount For Medicare Drug Negotiation Challengers No Photo Available

Yeji Jesse Lee

Big Pharma's losses in challenges to Medicare drug price negotiations are piling up. But don't think the industry is ready to wave the white flag.

High Court Interest In Health Sharing Ministry Case No Photo Available

Hannah Albarazi

The U.S. Supreme Court is showing interest in a challenge to state regulatory authority over health care sharing ministries. The nonpr... (more story)

Chatbots And Mental Health: Cases And New Laws To Know No Photo Available

Dan McKay

A Texas investigation into the marketing of chatbots as a mental health tool adds to the growing scrutiny on the use of the bots to mi... (more story)